trending Market Intelligence /marketintelligence/en/news-insights/trending/cqap1qmmhm6i8ylb9ieqwg2 content esgSubNav
In This List

Oncolytics Biotech raises $8.9M via common stock offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Oncolytics Biotech raises $8.9M via common stock offering

Oncolytics Biotech Inc. sold 1,532,278 common shares at $5.83 apiece for gross proceeds of about $8.9 million in a public offering.

The shares sold included 160,065 common shares issued as part of the underwriters' overallotment option.

Ladenburg Thalmann & Co. Inc. acted as the sole book-running manager for the offering.

Alberta, Canada-based Oncolytics Biotech is a development stage biopharmaceutical company, which focuses on the discovery and development of pharmaceutical products to treat cancer.